Comparison of 3-Drug Versus 4-Drug and PI Versus Non-PI Combinations as Initial HAART: Experience From 1998 to 2007

Abstract

Although established in controlled studies that there is no advantage to 4-drug highly active antiretroviral therapy (HAART) or regimens with or without protease inhibitors (PIs), we questioned this finding in a clinical setting (ie, no inclusion criteria). Ours is a single clinic retrospective study including all participants >18 years of age during their first year of HAART. A total of 190 participants were reviewed, with 168 (88%) attaining a viral load <400 copies/mL at the end of a year of HAART; 144 of 164 (88%) succeeded with 3 drugs and 24 of 26 (92%) with 4 drugs (P = .51). In all, 59 of 71 (83%) succeeded using a PI versus 109 of 119 (92%) without a PI (P = .08). Male gender and exposure time to HAART were significant variables for a successful outcome. Failures were due to side effects (50%), nonadherence (45%), and drug allergy (5%). Our results support current guidelines recommending 3-drug HAART.

Keywords

protease inhibitors nucleoside reverse transcriptase inhibitors treatment naive HIV

References

Hammer SM , Squires KE , Hughes MD , et al., for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337(11):725-733.

Palella FJ Jr , Delaney KM , Moorman AC , et al., and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-860.

Hirsch MS , Günthard HF , Schapiro JM , et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47(2):266-285.

Gulick RM , Ribaudo HJ , Shikuma CM , et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296(7): 769-781.

Chesney MA Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 2):S171-S176.

Ngo C. , Sansgiry SS Comment: factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother. 2004;38(3):511; author reply 511.

Escobar I. , Campo M. , Martín J. , Fernández-Shaw C. , Pulido F. , Rubio R. Factors affecting patient adherence to highly active antiretroviral therapy . Ann Pharmacother. 2003;37(6):775-781.

Ramírez García P. , Côté JK Factors affecting adherence to antiretroviral therapy in people living with HIV/AIDS. J Assoc Nurses AIDS Care. 2003;14(4):37-45.

Lafeuillade A. Factors affecting adherence and convenience in antiretroviral therapy. Int J STD AIDS. 2001;12(suppl 4):18-24.

10.

Moore AL , Kirk O. , Johnson AM , et al., for the EuroSIDA Group. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr. 2003;32(4):452-461.

11.

Gordillo V. , del Amo J. , Soriano V. , González-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13(13):1763-1769.

12.

Riddler SA , Haubrich R. , DiRienzo AG , et al., for the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008; 358(20):2095-2106.